Skip to main content

Vor Biopharma Inc.

VOR
Exchange
Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
SEC CIK
0001817229

In the last 90 days, Vor Biopharma Inc. insiders filed 0 open-market purchases and 1 sale; 102 institutions reported holding it in 13F filings for Q2 2026, worth $893.0M in total; no superinvestor holds it.

Q4 2024 vs. Q3 2024

How the institutions holding Vor Biopharma Inc. changed between Q3 2024 and Q4 2024.

All holders in Q4 2024All holders in Q3 2024

13F holders of VOR: Q3 2024 compared with Q4 2024
MeasureQ3 2024Q4 2024Change
Holders5452−2
Shares47.8M60.9M+13.1M (+27.4%)
Value$33.5M$67.6M+$34.2M (+102.0%)

New holders (14)

Institutions that held Vor Biopharma Inc. at the end of Q4 2024 but not at the end of Q3 2024.

Institutions new to VOR in Q4 2024
InstitutionSharesValue% of portfolio
Lynx1 Capital Management LP637,218$707.3K0.27%
Susquehanna International Group, LLP115,028$127.7K0.00%
Trustees of Columbia University in the City of New York91,910$102.0K0.02%
XTX Topco Ltd71,788$79.7K0.01%
Virtu Financial LLC54,470$60.0K0.00%
Gabelli & Co Investment Advisers, Inc.30,000$33.3K0.01%
Cubist Systematic Strategies, LLC16,102$17.9K0.00%
Two Sigma Securities, LLC10,069$11.2K0.00%
Wedbush Securities Inc10,000$11.0K0.00%
Group One Trading, L.P.2,422$2.69K0.00%
BNP Paribas Arbitrage, SA1,149$1.27K0.00%
SBI Securities Co., Ltd.481$5340.00%
Citigroup Inc6$70.00%
NBC Securities, Inc.1$10.00%

Sold out (16)

Institutions that held Vor Biopharma Inc. at the end of Q3 2024 and filed for Q4 2024 without it.